The Interface of Therapeutics and Genomics in Cardiovascular Medicine.

ABSTRACT: Pharmacogenomics has a burgeoning role in cardiovascular medicine, from warfarin dosing to antiplatelet choice, with recent developments in sequencing bringing the promise of personalised medicine ever closer to the bedside. Further scientific evidence, real-world clinical trials, and economic modelling are needed to fully realise this potential. Additionally, tools such as polygenic risk scores, and results from Mendelian randomisation analyses, are only in the early stages of clinical translation and merit further investigation. Genetically targeted rational drug design has a strong evidence base and, due to the nature of genetic data, academia, direct-to-consumer companies, healthcare systems, and industry may meet in an unprecedented manner. Data sharing navigation may prove problemati

SUBMITTER: Magavern EF 

PROVIDER: S-EPMC7851637 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature